Technique can be used to better categorize patients with neurological disease, according to their therapeutic needs
Personalized medicine delivering therapies specially tailored to a patients unique physiology has been a goal of researchers and doctors for a long time. New research provides a way of delivering personalized treatments to patients with neurological disease.
Researchers at the Montreal Neurological Institute and Hospital (The Neuro) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health have developed what they call a personalized Therapeutic Intervention Fingerprint (pTIF). The pTIF predicts the effectiveness of targeting specific biological factors (brain amyloid/tau deposition, inflammation, neuronal functional dysregulation) for controlling the evolution of the patients disease. Their results were published in the journal Neuroimage on June 14, 2018.
Lead by the studys first author, Yasser Iturria-Medina, researchers used computational brain modeling and artificial intelligence techniques to analyze the neurological data from 331 Alzheimers patients and healthy controls. The data included multiple modes of positron emission tomography (PET) and magnetic resonance imaging (MRI). From this, Iturria-Medina and colleagues were able to categorize patients into their TIF subtypes, according to the potentially most beneficial factor-specific interventions.
The authors verified these subtypes were relevant by comparing them to the patients individual genetic profiles. They found patients in the same pTIF subtype had similar gene expression, meaning the mechanism in which genes affect their physiology is similar. Because drugs to control disease progression would have to modify gene expression and brain properties at the same time, drugs tailored to pTIF subtypes would be much more effective than drugs designed to treat all Alzheimers disease patients.
This is the first study to pinpoint a direct link between brain dynamics, predicted therapeutic responses, and molecular and cognitive alterations in patients. Using pTIF subtypes, drugs can be designed for a patients unique gene expression profile and phenotypic brain characteristics, which is a major advancement in personalized medicine. It could also improve the effectiveness and reduce the cost of clinical drug trials if used as a method to select patients.
In keeping with the tenets of personalized medicine, the introduced framework could lead to more effective medical care, decreased undesired secondary effects, and substantial reduction of pharmaceutical/clinical costs associated with clinical trials, thereby accelerating the creation-evaluation cycle of new therapeutic agents, says Iturria-Medina. Our future work will focus on applying the pTIF to other neurological disorders, extensively validating it, and, importantly, making the resulting analytic tools available to the international community, viaopen-access platforms.
This research was funded by the Government of Canadas Banting postdoctoral fellowship and Brain Canada through the Canada Brain Research Fund with the financial support of Health Canada, whereas data collection was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) and its associated institutions.
The Montreal Neurological Institute and Hospital The Neuro is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the worlds top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre.